<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; in</title>
	<atom:link href="http://www.tapanray.in/tag/in/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Growing Intricacies of Today’s Field Staff Role And The Path Ahead</title>
		<link>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=growing-intricacies-of-todays-field-staff-role-and-the-path-ahead</link>
		<comments>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/#comments</comments>
		<pubDate>Mon, 30 Jan 2023 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[e-detailing]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[field. staff]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[hybridization]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intricacies]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[pull]]></category>
		<category><![CDATA[Push]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10742</guid>
		<description><![CDATA[With a varying degree, and in various forms, a hybrid working model is now gaining greater acceptance of several top pharma companies, across the world, just as in many other industries. This trend gets echoed in an article of December 07, 2022, &#8230; <a href="http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does ‘Free-Market Economy’ Work For Branded Generic Drugs In India?</title>
		<link>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-free-market-economy-work-for-branded-generic-drugs-in-india</link>
		<comments>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/#comments</comments>
		<pubDate>Mon, 27 Apr 2015 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Badm Medicine]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[chemicals. and. fertilizers]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[Delhi School of Economics]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DoP. department of pharmaceuticals]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DSE]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[Free Market Economy]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[IJME]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[paradox]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[‘Dorfman-Steiner’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6557</guid>
		<description><![CDATA[On April 20, 2015, a panel of 31 lawmakers of the Standing Committee on Chemicals and Fertilizers tabled its report in the Indian Parliament. The committee emphasized that patients in India should have access to all medicines, including life saving drugs, &#8230; <a href="http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Make in India…Sell Anywhere in The World”: An Indian Pharma Perspective</title>
		<link>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective</link>
		<comments>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/#comments</comments>
		<pubDate>Mon, 29 Sep 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[alert]]></category>
		<category><![CDATA[anywhere]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Bureau]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[day]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global. world]]></category>
		<category><![CDATA[Harvard]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[independence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[letters]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmexcil]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[production]]></category>
		<category><![CDATA[ramparts. red fort]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[sell]]></category>
		<category><![CDATA[speech]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[warning]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6039</guid>
		<description><![CDATA[In his Independent Day speech from the ramparts of the Red Fort on August 15, 2014, Indian Prime Minister Modi gave a clarion call to all investors of the world, “Come, make in India”, “Come, manufacture in India”, “Sell in &#8230; <a href="http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Fire in The Blood”: A Ghastly Patents Vs Patients War &#8211; for Pricing Freedom?</title>
		<link>http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom</link>
		<comments>http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/#comments</comments>
		<pubDate>Mon, 07 Oct 2013 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[blood]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[CSR]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Dylan]]></category>
		<category><![CDATA[fire]]></category>
		<category><![CDATA[ghastly]]></category>
		<category><![CDATA[Gray]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Mohan]]></category>
		<category><![CDATA[obscene]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[war]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3776</guid>
		<description><![CDATA[International award winning documentary film, &#8216;FIRE IN THE BLOOD&#8217; could possibly set a raging fire in your blood too, just like mine. It made me SAD, REFLECTIVE and ANGRY, prompting to share &#8216;MY TAKE AWAYS&#8217; with you on this contentious subject, immediately after I put &#8230; <a href="http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Two Paintings on the Same Canvas: &#8216;Truth About Drug Companies&#8217; and &#8216;Protecting Access to Medicines&#8217;</title>
		<link>http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines</link>
		<comments>http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/#comments</comments>
		<pubDate>Mon, 13 May 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[about]]></category>
		<category><![CDATA[About It.]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Angell]]></category>
		<category><![CDATA[book]]></category>
		<category><![CDATA[canvas]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Deceive]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Editor]]></category>
		<category><![CDATA[England]]></category>
		<category><![CDATA[Forbes]]></category>
		<category><![CDATA[former]]></category>
		<category><![CDATA[foundation]]></category>
		<category><![CDATA[Harvard]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[her]]></category>
		<category><![CDATA[How]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[leading]]></category>
		<category><![CDATA[M.D.faculty]]></category>
		<category><![CDATA[Marcia]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NEJM]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[paintings]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[protecting]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[same]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[Srinath]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[TheTruth]]></category>
		<category><![CDATA[they]]></category>
		<category><![CDATA[titled]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[What to]]></category>
		<category><![CDATA[world’s]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2280</guid>
		<description><![CDATA[As the saying goes, &#8220;Great people think alike&#8221;, many thought leaders of very high credibility across the globe, seem to think almost in similar lines when it comes to improving access to medicines for a large section of the global &#8230; <a href="http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/two-paintings-on-the-same-canvas-truth-about-drug-companies-and-protecting-access-to-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Robust implementation of Biosimilar Guidelines could help India earn leadership status in ‘Biosimilar World’</title>
		<link>http://www.tapanray.in/robust-implementation-of-biosimilar-guidelines-could-help-india-earn-leadership-status-in-biosimilar-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=robust-implementation-of-biosimilar-guidelines-could-help-india-earn-leadership-status-in-biosimilar-world</link>
		<comments>http://www.tapanray.in/robust-implementation-of-biosimilar-guidelines-could-help-india-earn-leadership-status-in-biosimilar-world/#comments</comments>
		<pubDate>Mon, 05 Nov 2012 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[could]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[earn]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[help]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[status]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1072</guid>
		<description><![CDATA[Across the world, biologic drugs, in general, have a successful record in treating many life threatening and other complicated ailments. Expiration of product patents of the first major group of originators&#8217; biologic molecules has led to the development of products &#8230; <a href="http://www.tapanray.in/robust-implementation-of-biosimilar-guidelines-could-help-india-earn-leadership-status-in-biosimilar-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/robust-implementation-of-biosimilar-guidelines-could-help-india-earn-leadership-status-in-biosimilar-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients”: Exploring the book to be released in the Indian context</title>
		<link>http://www.tapanray.in/bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context</link>
		<comments>http://www.tapanray.in/bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context/#comments</comments>
		<pubDate>Mon, 15 Oct 2012 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Bad]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[book]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[context]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[Exploring]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Harm]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[How]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Mislead]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[released]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1081</guid>
		<description><![CDATA[The title of today’s article could make some of the readers uncomfortable and angry, just as what I experienced while writing the same, being a long time follower and student of the pharmaceutical industry, both global and local. Ethical business &#8230; <a href="http://www.tapanray.in/bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/bad-pharma-how-drug-companies-mislead-doctors-and-harm-patients-exploring-the-book-to-be-released-in-the-indian-context/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Early Signal of Metamorphosis in the Global Pharmaceutical Product Patent Regime</title>
		<link>http://www.tapanray.in/early-signal-of-metamorphosis-in-the-global-pharmaceutical-product-patent-regime/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=early-signal-of-metamorphosis-in-the-global-pharmaceutical-product-patent-regime</link>
		<comments>http://www.tapanray.in/early-signal-of-metamorphosis-in-the-global-pharmaceutical-product-patent-regime/#comments</comments>
		<pubDate>Mon, 17 Sep 2012 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Early]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[signal]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=31</guid>
		<description><![CDATA[Before enactment of the Indian Patents Act (amended) 2005, it was widely reported that to protect ‘Public Health Interest’, the Parliament of India has ensured inclusion of a number of ‘safeguards’ including checks on &#8216;ever-greening&#8217; of pharmaceutical patents and broader &#8230; <a href="http://www.tapanray.in/early-signal-of-metamorphosis-in-the-global-pharmaceutical-product-patent-regime/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/early-signal-of-metamorphosis-in-the-global-pharmaceutical-product-patent-regime/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Concept of Orphan Drugs for Orphan Diseases is Orphan in India</title>
		<link>http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india</link>
		<comments>http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/#comments</comments>
		<pubDate>Mon, 10 Sep 2012 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Concept]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=36</guid>
		<description><![CDATA[Though the percentage of patients suffering from ‘Rare Diseases’ in India is reportedly higher than the  world average, unfortunately even today such cases get little help from our government. According to experts, diseases manifesting patients representing maximum 6 to 8 &#8230; <a href="http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Replication of ‘Old Paradigm’ of the developed pharmaceutical markets is unlikely to yield results in the evolving new paradigm of India</title>
		<link>http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india</link>
		<comments>http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/#comments</comments>
		<pubDate>Mon, 03 Sep 2012 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[developed]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[evolving]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Replication]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[results]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[unlikely]]></category>
		<category><![CDATA[yield]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=40</guid>
		<description><![CDATA[“Health leaps out of science and draws nourishment from the society around it” - Gunnar Myrdal (Swedish Nobel Laureate Economist) The success concoction of the global pharmaceutical industry for India, by and large, still remains to be sustained attempts in &#8230; <a href="http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/replication-of-old-paradigm-of-the-developed-pharmaceutical-markets-is-unlikely-to-yield-results-in-the-evolving-new-paradigm-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
